First Cancer Patients in Africa Treated with the TomoTherapy® System

Sunnyvale, California (ots/PRNewswire) - Premier Algerian Cancer
Center Now Provides Cancer Patients with Leading-Edge Radiation
Treatments

Accuray Incorporated (NASDAQ: ARAY) announced today that the newly
built Radiotherapy and Medical Oncology Center of Sidi Abdellah,
Algeria is now treating cancer patients with the first TomoTherapy®
Systems installed in Africa. The TomoTherapy System is recognized
worldwide for providing highly precise treatments for a broad range
of cancer cases, from routine to complex. The first treatment was
successfully delivered in February 2017 to a patient with breast
cancer.

(Logo: http://photos.prnewswire.com/prnh/20151126/291246LOGO )

(Photo: http://mma.prnewswire.com/media/487840/Accuray.jpg )

The TomoTherapy Systems are two out of three Accuray systems to be
installed and operated at the Center, located not far from the
Technoparc of Sidi Abdellah in the suburbs of Algiers. The
Radiotherapy and Medical Oncology Center also purchased one
CyberKnife® M6(TM) System which is scheduled to be installed by the
end of 2018. With the two systems - CyberKnife and TomoTherapy - in
one location, the Center will have the flexibility to efficiently and
effectively treat virtually all patients who may benefit from this
highly precise form of radiation therapy.

"We are honored that the Radiotherapy and Medical Oncology Center
team has selected the Accuray systems to expand their cancer
treatment options. Their decision reinforces growing global
recognition of the importance of radiation therapy in treating
cancer," said Lionel Hadjadjeba, MD, Corporate Senior Vice President
and President of Worldwide Commercial Operations at Accuray. "The
TomoTherapy and CyberKnife Systems provide an optimal combination of
efficacy and safety while minimizing the impact of treatment on daily
lives, and will enable the clinical team to confidently provide each
cancer patient with a treatment program that addresses his or her
individual needs."

In Algeria, 45,000 new cases of cancer are diagnosed each year [1].
The acquisition of these new technologies is in accordance with the
Algerian Cancer Plan 2015-2019 which, among other measures, aims to
improve the performance of radiotherapy services, shorten times to
obtain radiotherapy appointments, and improve the quality and safety
of care in radiotherapy [1].

"I am very pleased and proud to offer, at the Radiotherapy and
Medical Oncology Center of Sidi Abdellah, a full range of treatment
options: from chemotherapy to brachytherapy and now, treatment with
the TomoTherapy System. With this leading-edge and innovative
radiation therapy device, we can deliver precise, safe and
individualized radiation treatments to a wide range of tumor types
while preserving surrounding healthy tissue," said Prof. Mustapha
Yaker, Director of the Radiotherapy and Medical Oncology Center of
Sidi Abdellah. "Maintaining the patient's quality of life during and
post-treatment is a top priority and I believe the TomoTherapy System
will help us accomplish this goal."

Based on a CT scanner platform, the TomoTherapy System provides
continuous delivery of radiation from 360 degrees around the patient,
or delivery from clinician-specified beam angles. These unique
features, combined with daily 3D image guidance, enable physicians to
deliver highly accurate, individualized dose distributions which
precisely conform to the shape of the patient's tumor while
minimizing dose to normal, healthy tissue, resulting in fewer side
effects for patients. The TomoTherapy System is capable of treating
all standard radiation therapy indications including breast,
prostate, lung and head and neck cancers, in addition to complex
treatments such as total marrow irradiation.

The CyberKnife System delivers radiosurgery and stereotactic body
radiation therapy (SBRT), enabling precise, high quality dose
distributions to be confidently administered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. Using its unique
robotic range of motion and continuous image guidance, the system
follows the target throughout the treatment process, delivering
individualized treatment with sub-millimeter precision.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures, and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation therapy
and radiosurgery treatments. For more information, please visit
http://www.accuray.com .

Safe Harbor Statement

Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, clinical results,
market acceptance of our new technologies, patient outcomes and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24, 2016, the company's reports
on Form 10-Q, filed on November 1, 2016 and February 3, 2017, and as
updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements
are made and are based on information available to Accuray at the
time those statements are made and/or management's good faith belief
as of that time with respect to future events. The company assumes no
obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other
factors affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors should
not put undue reliance on any forward-looking statements.

References

1. Zitouni M., Algeria's Cancer Plan 2015-2019. http://www.santemaghr
   eb.com/algerie/comscien_pdf/cancer_plan_algerie_marrakech.pdf  
2. Atun F, et al. The Lancet Oncology Commission. Expanding global 
   access to radiotherapy. The Lancet Oncology 2015; 16(10):1153-86.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print